# Intra-Cellular Therapies, Inc.  Share Price Target ‘$132.73’, now 3.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/intra-cellular-therapies-inc-share-price-target-132-73-now-3-7-upside-potential/4121187045
- Published: 2025-02-20T16:45:08+00:00
- Author: Charlotte Edwards

**Intra-Cellular Therapies, Inc.** with ticker code (ITCI) have now 11 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between $140.00 and $132.00 calculating the mean target share
price we have $132.73. (at the time of writing). Now with the previous closing price
of $127.96 and the analysts are correct then there would likely be a percentage 
uptick in value of 3.7%. Also worth taking note is the 50 day moving average now
sits at $106.76 and the 200 day moving average is $83.16. The market capitalization
for the company is 13.67B. Currently the stock stands at: $128.60 USD

 The potential market cap would be $14,182,542,714 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $6.10 and
a -7.45% return on assets.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused
on the discovery, clinical development and commercialization of small molecule drugs
that address underserved medical needs primarily in neuropsychiatric and neurological
disorders by targeting intracellular signaling mechanisms within the central nervous
system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes
associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy
and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 
mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled
bipolar depression studies, which evaluated the effects of CAPLYTA on depression
in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study
404) and as adjunctive therapy with lithium or valproate (Study 402).

Share on: